Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Victoza Outperforms Byetta In Head-To-Head Trial

This article was originally published in The Pink Sheet Daily

Executive Summary

Head-to-head trial results presented at the American Diabetes Association meeting are positive, but safety questions aren't likely to go away.

You may also be interested in...



Sanofi/Zealand Release Head-To-Head Data For Lixisenatide Vs. Exenatide

Once-a-day here to stay? With once-weekly taspoglutide just officially rejected by Roche and long-lasting Bydureon delayed on safety, Zealand CEO talks up the virtues of QD GLP-1 analogs.

Sanofi/Zealand Release Head-To-Head Data For Lixisenatide Vs. Exenatide

Once-a-day here to stay? With once-weekly taspoglutide just officially rejected by Roche and long-lasting Bydureon delayed on safety, Zealand CEO talks up the virtues of QD GLP-1 analogs.

Sanofi/Zealand Release Head-To-Head Data For Lixisenatide Vs. Exenatide

Sanofi-Aventis and Zealand Pharma have gained some ammunition as they prepare to enter the competitive GLP-1 agonist market, with data from a head-to-head study showing their lixisenatide to be non-inferior to Lilly/Amylin's Byetta (exenatide).

Related Content

Topics

UsernamePublicRestriction

Register

OM013164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel